
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines, formerly known as BeiGene, reported a strong financial position with US$2.6 billion in cash at the end of 2024, which positions the company well for future growth and investment in its research and development. The company's flagship drug, Brukinsa, generated sales of US$2.6 billion in 2024, reflecting a remarkable year-over-year increase of 105%, indicating significant market acceptance and capturing over 68% of total sales. Additionally, BeOne's overall revenue forecasts have been raised for the coming years, bolstered by strong sales momentum for Brukinsa and Tevimbra, which demonstrated a solid performance against competitors, thereby enhancing the company's market share and solidifying its competitive positioning in the oncology therapeutics market.
Bears say
BeiGene's financial outlook remains concerning due to a significant decline in cash flow from operations, with fourth-quarter cash flow falling to US$75 million from US$188 million in the previous quarter, primarily driven by increased receivables and inventory. The company is experiencing substantial net losses, reported at US$645 million for the period, despite a narrowing of losses by 27% year-over-year, indicating ongoing financial challenges. Furthermore, downward revisions in revenue projections for key products, including a reduction in peak sales estimates for Tevimbra and ociperlimab, highlight increased uncertainty and risk to BeiGene's future profitability.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares